Who are the top shareholders of the Titan Biotech?

The top shareholders of Titan Biotech include Titan Securities Ltd with 33.59%, while individual investors hold 29.2%. The highest public shareholder is Ankit Goyal, owning 1.57%, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Titan Biotech primarily consist of its promoters, with Titan Securities Ltd holding the largest share at 33.59%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Ankit Goyal, who owns 1.57%. Additionally, individual investors collectively hold 29.2% of the company's shares.

When is the next results date for Titan Biotech?

No Upcoming Board Meetings

What does Titan Biotech do?

Titan Biotech Ltd. manufactures Biological Peptones, Extracts, and Dehydrated Culture media, focusing on products that promote microorganism growth. As of March 2025, it reported net sales of 35 Cr and a net profit of 4 Cr, with a market cap of Rs 348 Cr.

Overview:<BR>Titan Biotech Ltd. is a company engaged in the manufacture of Biological Peptones, Extracts, and Dehydrated Culture media, operating within the Specialty Chemicals industry and classified as a Micro Cap.<BR><BR>History:<BR>Titan Biotech Ltd. is based in New Delhi and has been incorporated to focus on the production of products conducive to the growth of microorganisms. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 35 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 348 Cr (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 16.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.48% <BR>Debt-Equity: -0.02 <BR>Return on Equity: 14.04% <BR>Price to Book: 2.24 <BR><BR>Contact Details:<BR>Address: A-902 A RIICO Industrial Area, Phase III Alwar District Bhiwadi Rajasthan : 301019 <BR>Tel: 91-011-27355742/27674615 <BR>Email: cs@titanbiotechltd.com/hrd@titanbio <BR>Website: http://www.titanbiotechltd.com

Has Titan Biotech declared dividend?

Titan Biotech Ltd has declared a 20% dividend, amounting to 2 per share, with an ex-date of September 23, 2024. Recent total returns show significant fluctuations, with a -51.52% return over the last 6 months, but positive growth over longer periods, including a 519.38% return over the past 5 years.

Titan Biotech Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.48%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -51.52%, with a dividend return of 0%, resulting in a total return of -51.52%.<BR><BR>Over the past year, the price return was -20.31%, the dividend return was 0.38%, leading to a total return of -19.93%.<BR><BR>In the 2-year period, the price return was 56.16%, the dividend return was 1.46%, resulting in a total return of 57.62%.<BR><BR>For the 3-year period, the price return was 85.88%, with a dividend return of 2.49%, culminating in a total return of 88.37%.<BR><BR>In the last 4 years, the price return was 38.8%, the dividend return was 1.72%, resulting in a total return of 40.52%.<BR><BR>Over the past 5 years, the price return was 509.14%, with a dividend return of 10.24%, leading to a total return of 519.38%.<BR><BR>Overall, Titan Biotech has declared a dividend, but the recent total returns indicate significant fluctuations, particularly in the short term, with negative returns over the last 6 months and 1 year, while longer-term returns show substantial growth.

Who are the peers of the Titan Biotech?

Titan Biotech's peers include Pidilite Inds., SRF, Gujarat Fluoroch, and others. In terms of management risk, Titan Biotech has a good rating, with a 1-year return of -20.52%, higher than Chembond Chem. but lower than SRF's 30.49%.

Peers: The peers of Titan Biotech are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Multibase India, Diamines & Chem., Dynemic Products, Chembond Chem., and Vipul Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Pidilite Inds., SRF, Deepak Nitrite, and Diamines & Chem., while Good management risk is found at Titan Biotech and Vipul Organics. Average management risk is present at Gujarat Fluoroch, Himadri Special, Multibase India, Dynemic Products, and Chembond Chem. For Growth, Excellent growth is noted at Himadri Special, while Average growth is seen at Pidilite Inds., SRF, and Chembond Chem. Below Average growth is found at Gujarat Fluoroch, Deepak Nitrite, Titan Biotech, Diamines & Chem., Multibase India, Dynemic Products, and Vipul Organics. In terms of Capital Structure, Excellent capital structure is noted at Pidilite Inds., SRF, Deepak Nitrite, Titan Biotech, and Diamines & Chem., while Good capital structure is found at Himadri Special, and Average capital structure is observed at Multibase India and Dynemic Products, with the rest having Below Average.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SRF at 30.49%, while the lowest is Chembond Chem. at -53.33%. Titan Biotech's 1-year return is -20.52%, which is higher than Chembond Chem. but lower than SRF. Additionally, the peers with negative six-month returns include Deepak Nitrite, Multibase India, Diamines & Chem., Dynemic Products, Chembond Chem., and Titan Biotech.

Who are in the management team of Titan Biotech?

As of March 2022, the management team of Titan Biotech includes Naresh Kumar Singla and Suresh Chand Singla as Managing Directors, along with several other directors and officers, totaling a mix of executive and non-executive roles.

As of March 2022, the management team of Titan Biotech includes the following individuals:<BR><BR>1. Naresh Kumar Singla - Managing Director<BR>2. Suresh Chand Singla - Managing Director<BR>3. Manju Singla - Non-Executive & Non-Independent Director<BR>4. Charanjit Singh - Company Secretary & Compliance Officer<BR>5. Supriya Singla - Non-Executive & Non-Independent Director<BR>6. Rekha Dalmia - Non-Executive & Independent Director<BR>7. Rohit Jain - Independent Director<BR>8. Abhishek Agarwal - Independent Director<BR>9. Raja Singla - Whole-time Director<BR><BR>This team comprises a mix of executive and non-executive directors, with two individuals serving as managing directors.

How big is Titan Biotech?

As of 24th July, Titan Biotech Ltd has a market capitalization of 374.00 Cr, with recent net sales of 156.45 Cr and a net profit of 21.54 Cr. Shareholder's funds are 133.45 Cr, and total assets amount to 156.58 Cr.

As of 24th July, Titan Biotech Ltd has a market capitalization of 374.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Titan Biotech reported Net Sales of 156.45 Cr and a Net Profit of 21.54 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 133.45 Cr and Total Assets of 156.58 Cr.

Is Titan Biotech overvalued or undervalued?

As of August 18, 2025, Titan Biotech is considered very expensive and overvalued, with a PE ratio of 17.32, an EV to EBITDA of 14.59, and a Price to Book Value of 2.48, especially when compared to peers like Solar Industries and Godrej Industries, despite a recent stock performance uptick.

As of 18 August 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant deterioration in its valuation outlook. The company is currently deemed overvalued. Key ratios include a PE ratio of 17.32, an EV to EBITDA of 14.59, and a Price to Book Value of 2.48, which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison with peers, Titan Biotech's PE ratio is notably lower than that of Solar Industries, which stands at 108.25, and Godrej Industries, which has a PE ratio of 42.48, reinforcing the perception of Titan's overvaluation. Furthermore, despite a recent uptick in stock performance with a 4.18% return over the past week compared to a modest 0.83% for the Sensex, the year-to-date return of -37.09% highlights ongoing challenges. Overall, Titan Biotech's current valuation metrics and peer comparisons suggest that it is overvalued in the specialty chemicals sector.

Are Titan Biotech latest results good or bad?

Titan Biotech's latest Q2 FY26 results are generally positive, with a 69.38% increase in net profit and a 32.21% rise in net sales quarter-on-quarter. However, while showing strong recovery, the company faces challenges with margin volatility and negative EBIT growth over the past five years, indicating mixed long-term prospects.

Titan Biotech's latest results for Q2 FY26 can be viewed as generally positive, showcasing a strong recovery compared to the previous quarter. The consolidated net profit surged to ₹6.86 crores, reflecting a remarkable 69.38% increase quarter-on-quarter and a 7.19% rise year-on-year. Additionally, net sales rose to ₹46.50 crores, marking a 32.21% increase from the previous quarter and a 7.86% increase compared to the same period last year.<BR><BR>The operating margin also improved significantly, reaching 18.80%, which is a notable recovery from 12.99% in the previous quarter, although it remains slightly below the 19.14% achieved in Q2 FY25. This indicates that while the company is experiencing a rebound, it still faces challenges in maintaining consistent margins.<BR><BR>Overall, while the quarterly performance shows strong sequential growth, the year-on-year figures suggest that Titan Biotech is on a modest growth trajectory. The company operates in a competitive environment with inherent margin volatility, which investors should keep in mind. The balance sheet remains strong, with a solid return on equity of 25.08%, indicating effective capital utilization. However, the long-term growth outlook is tempered by concerns over negative EBIT growth over the past five years, suggesting that while the recent results are good, there are underlying challenges that may affect future performance.

How has been the historical performance of Titan Biotech?

Titan Biotech's historical performance shows fluctuating financial metrics, with net sales and profits declining from Mar'24 to Mar'25, despite an increase in total assets. Operating profit decreased significantly, indicating challenges in profitability.

Answer:<BR>The historical performance of Titan Biotech shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Titan Biotech's net sales have shown variability, with a peak of 164.07 Cr in Mar'24, followed by a decline to 156.45 Cr in Mar'25. Total operating income mirrored this trend, reaching 164.07 Cr in Mar'24 before decreasing to 156.45 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 129.79 Cr in Mar'24 to 131.02 Cr in Mar'25. Operating profit (PBDIT) also saw a decline from 34.28 Cr in Mar'24 to 25.43 Cr in Mar'25, reflecting a decrease in operating profit margin from 20.89% to 16.25%. Profit before tax decreased from 31.53 Cr in Mar'24 to 24.37 Cr in Mar'25, leading to a profit after tax of 18.27 Cr in Mar'25, down from 23.66 Cr in Mar'24. The consolidated net profit followed suit, decreasing from 24.85 Cr in Mar'24 to 21.53 Cr in Mar'25. On the balance sheet, total assets rose from 157.03 Cr in Mar'24 to 174.71 Cr in Mar'25, while total liabilities also increased from 157.03 Cr to 174.71 Cr. The company maintained a stable equity capital of 8.26 Cr over the years. Cash flow from operating activities remained relatively stable, with a slight decrease from 21.00 Cr in Mar'24 to 20.00 Cr in Mar'25, while net cash inflow improved from a negative 2.00 Cr in Mar'24 to a positive 2.00 Cr in Mar'25. Overall, Titan Biotech's financial performance reflects challenges in profitability despite growth in total assets.

Should I buy, sell or hold Titan Biotech?

Is Titan Biotech technically bullish or bearish?

As of November 18, 2025, Titan Biotech's technical trend is mildly bullish, supported by bullish MACD and Bollinger Bands, despite mixed signals from KST and a mildly bearish Dow Theory.

As of 18 November 2025, the technical trend for Titan Biotech has changed from bullish to mildly bullish. The weekly MACD remains bullish, supporting a positive outlook, while the monthly MACD is also bullish, indicating strength over a longer time frame. The Bollinger Bands are showing a mildly bullish stance on both weekly and monthly charts, which aligns with the daily moving averages that are also mildly bullish. However, the KST indicates a mixed signal with a bullish weekly reading but a mildly bearish monthly reading. The Dow Theory shows a mildly bearish stance on the weekly chart, suggesting some caution. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands, despite some mixed signals from KST and Dow Theory.

Which are the latest news on Titan Biotech?

Why is Titan Biotech falling/rising?

As of 03-Dec, Titan Biotech Ltd's stock price is 978.10, down 0.39%, with a recent decline in investor participation and a 1-week return of -4.19%. Despite a strong year-to-date increase of 33.48%, the stock is currently facing negative sentiment.

As of 03-Dec, Titan Biotech Ltd's stock price is currently at 978.10, reflecting a decrease of 3.85 points or 0.39%. The stock has been experiencing a downward trend, having fallen for the last two consecutive days, resulting in a total decline of 1.48% during this period. Additionally, the stock has underperformed in the short term, with a 1-week return of -4.19%, while the benchmark Sensex has only decreased by 0.59% in the same timeframe.<BR><BR>Investor participation has also diminished, as evidenced by a significant drop in delivery volume, which fell by 65.03% compared to the 5-day average. This decline in trading activity may indicate reduced interest from investors, contributing to the stock's price decline. Although the stock performed better than its sector today by 0.9% and has shown strong long-term growth with a year-to-date increase of 33.48%, the recent short-term performance and falling investor participation suggest a negative sentiment surrounding Titan Biotech Ltd at this time.